C12N 2750/14352
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2750/14352 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 14 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 15
- Assignees
- 12
- Inventors
- 36
- Latest grant
- 2 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 1 | 1 |
| 2017 | 1 | 1 |
| 2018 | 1 | 1 |
| 2019 | 1 | 2 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 1 | 2 |
| 2024 | 1 | 1 |
| 2025 | 3 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Optimized parvovirus H-1 production2 Sep 2025US 12,404,498 B2Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Canine parvovirus (CPV) nanobody CPV-VHH-H1 and use thereof29 Jul 2025US 12,371,476 B2Institute of Animal Sciences of Caas
- Establishment and suspension acclimation of CRFK adherent cell line, and its application29 Apr 2025US 12,286,647 B1Taizhou Bioally Technology Co., Ltd.
- Restrictive inverted terminal repeats for viral vectors26 Mar 2024US 11,939,597 B2The University of North Carolina at Chapel Hill
- Restrictive inverted terminal repeats for viral vectors3 Jan 2023US 11,542,478 B2The University of North Carolina at Chapel Hill
- Establishment and suspension acclimation of crfk adherent cell line, and its application24 Apr 2025US 2025/0129341 A1Taizhou Bioally Technology Co., Ltd.
- Protoparvovirus and tetraparvovirus compositions and methods for gene therapy29 Feb 2024US 2024/0066080 A1Synteny Therapeutics, Inc.
- Canine parvovirus (cpv) nanobody cpv-vhh-h1 and use thereof22 Jun 2023US 2023/0192815 A1Institute of Animal Sciences of Chinese Academy of Agricultural Sciences
- Restrictive inverted terminal repeats for viral vectors1 Jun 2023US 2023/0167418 A1The University of North Carolina at Chapel Hill
- Optimized parvovirus h-1 production2 Jun 2022US 2022/0169992 A1Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Most cited
By later US patents
- Restrictive inverted terminal repeats for viral vectors38US 9,169,494 B2The University of North Carolina at Chapel Hill · 2015
- Stable production of lentiviral vectors4US 9,441,245 B2MolMed SpA · 2016
- Feline cell capable of being cultured without animal-derived protein, and method for producing virus and method for producing vaccine using thereof2US 7,767,451 B2Kyoritsu Seiyaku Corporation · 2010
- Parvovirus vectors and their use1US 7,267,825 B1Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts · 2007
- Adenovirus derived helper virus for enhancing recombinant parvovirus production1US 9,803,219 B2Deutsches Krebsforschungszentrum · 2017